References
- Jung HY, Jeon Y, Park Y, et al. Better quality of life of peritoneal dialysis compared to hemodialysis over a two-year period after dialysis initiation. Sci Rep. 2019 Jul 16;9(1):10266. DOI:10.1038/s41598-019-46744-1
- Tam P. Peritoneal dialysis and preservation of residual renal function. Perit Dial Int. 2009 Feb;29 Suppl 2:S108–10.
- Li PK, Chow KM, Van de Luijtgaarden MW, et al. Changes in the worldwide epidemiology of peritoneal dialysis. Nat Rev Nephrol. 2017 Feb;13(2):90–103.
- Fresinius Medical Care. Fresenius medical care 2018 annual report 2018; p. 266.
- Pérez Fontan M, Rodríguez-Carmona A, García-Naveiro R, et al. Peritonitis-related mortality in patients undergoing chronic peritoneal dialysis. Perit Dial Int. 2005 May;25(3):274–284.
- Filiopoulos V, Biblaki D, Takouli L, et al. Swan-neck versus straight peritoneal dialysis catheter: long-term effect on patient and method survival. Indian J Nephrol. 2016 Sep;26(5):343–346.
- Peppelenbosch A, van Kuijk WH, Bouvy ND, et al. Peritoneal dialysis catheter placement technique and complications. NDT Plus. 2008 Oct;1(Suppl 4):iv23–28.
- Wikdahl AM, Engman U, Stegmayr BG, et al. One-dose cefuroxime i.V. and i.P. reduces microbial growth in PD patients after catheter insertion. Nephrol Dial Transplant. 1997 Jan;12(1):157–160.
- Twardowski ZJ. Peritoneal dialysis glossary III. Peritoneal Dialysis Int. 1990;10(2):173–175.
- Dell’aquila R, Rodighiero MP, Spano’ E, et al. Advances in the technology of automated, tidal, and continuous flow peritoneal dialysis. Peritoneal Dialysis Int. 2007;27(2_suppl):130–137. DOI:10.1177/089686080702702s22
- Warady BA 1, Eileen NE, Fivush BA, et al. Flush before fill” in children receiving automated peritoneal dialysis. Perit Dial Int. 2003 Sep;23(5):493–498.
- Maaz DE. Troubleshooting non-infectious peritoneal dialysis issues. Nephrol Nurs J. 2004 Sep;31(5): 521-32, 545.
- Dasgupta MK, Larabie M. Biofilms in peritoneal dialysis. Perit Dial Int. 2001;21(Suppl 3):S213–7.
- Pihl M, Davies JR, Johansson AC, et al. Bacteria on catheters in patients undergoing peritoneal dialysis. Perit Dial Int. 2013 Jan;33(1):51–59.
- Dasgupta MK, Kowalewska-Grochowska K, Larabie M, et al. Catheter biofilms and recurrent CAPD peritonitis. Adv Perit Dial. 1991;7:165–168. Erratum in: Adv Perit Dial 1992;8:478.
- Li PK, Chow KM, Cho Y, et al. ISPD peritonitis guideline recommendations: 2022 update on prevention and treatment. Perit Dial Int. 2022 Mar;42(2):110–153.
- Szeto CC, Li PKT. Peritoneal dialysis associated peritonitis. CJASN. 2019 Jul;14(7):1100–1105.
- Tranæus A, Heimbürger O, Lindholm B. Peritonitis during Continuous Ambulatory Peritoneal Dialysis (CAPD): risk factors, clinical severity, and pathogenetic aspects. Peritoneal Dialysis Int. 1988;8(4):253–263.
- Mujais S. Microbiology and outcomes of peritonitis in North America. Kidney Int Suppl. 2006 Nov;70(103):S55–62.
- Zeng Y, Jiang L, Lu Y, et al. Peritoneal dialysis-related peritonitis caused by gram-negative organisms: ten-years experience in a single center. Ren Fail. 2021 Dec;43(1):993–1003.
- Gadola L, Poggi C, Dominguez P, et al. Risk factors and prevention of peritoneal dialysis-related peritonitis. Perit Dial Int. 2019 Mar;39(2):119–125. Epub 2018 Sep 25. DOI:10.3747/pdi.2017.00287
- Szeto CC, Li PK, Johnson DW, et al. ISPD catheter-related infection recommendations: 2017 update. Peritoneal Dialysis Int. 2017;37:141–154.
- Lin J, Ye H, Li J, et al. Prevalence and risk factors of exit-site infection in incident peritoneal dialysis patients. Perit Dial Int. 2020 Mar;40(2):164–170.
- Ye H, Zhou Q, Fan L, et al. The impact of peritoneal dialysis-related peritonitis on mortality in peritoneal dialysis patients. BMC Nephrol. 2017 Jun 5;18(1):186. DOI:10.1186/s12882-017-0588-4
- Wang T, Cheng HH, Heimbürger O, et al. Effect of peritonitis on peritoneal transport characteristics: glucose solution versus polyglucose solution. Kidney Int. 2000 Apr;57(4):1704–1712.
- Szeto CC, Li PK, Johnson DW, et al. ISPD catheter-related infection recommendations: 2017 update. Perit Dial Int. 2017 Mar;37(2):141–154.
- Bong JJ, Kite P, Wilco MH, et al. Prevention of catheter related bloodstream infection by silver iontophoretic central venous catheters: a randomised controlled trial. J Clin Pathol. 2003;56:731–735.
- Crabtree JH, Burchette RJ, Siddiqi RA, et al. The efficacy of silver-ion implanted catheters in reducing peritoneal dialysis-related infections. Perit Dial Int. 2003;23:368–374.
- Finelli A, Burrows LL, DiCosmo FA, et al. Colonization-resistant antimicrobial-coated peritoneal dialysis catheters: evaluation in a newly developed rat model of persistent Pseudomonas aeruginosa peritonitis. Perit Dial Int. 2002;22:27–31.
- Kim CY, Kumar A, Sampath L, et al. Evaluation of an antimicrobial-impregnated continuous ambulatory peritoneal dialysis catheter for infection control in rats. Amer J Kidney Dis. 2002;39:165–273.
- Raad I, Darouiche RO, Dupuis J, et al. Central venous catheters coated with minocycline and rifampicin for the prevention of catheter-related colonization and bloodstream infections. A randomized double-blind trial. Ann Intern Med. 1997;127:267–274.
- Darouiche RO, Smith JA, Hanna H, et al. Efficacy of antimicrobial-impregnated bladder catheters in reducing catheter-associated bacteriuria: a prospective, randomized, multicenter clinical trial. Urol. 1999;54:976–981.
- Zabramski JM, Whiting D, Darouiche RO, et al. Efficacy of antimicrobial-impregnated external ventricular drain catheters: a prospective, randomized, controlled trial. J Neurosurg. 2003;98:725–730.
- Chatzninikolaou I, Hanna H, Graviss L, et al. Clinical experience with minocycline and rifampicin-impregnated central venous catheter in bone marrow transplantation recipients: efficacy and low risk of developing staphylococcal resistance. Infect Control Hosp Epidemiol. 2003;24:961–963.
- Bayston R, Grove N, Siegel J, et al. Prevention of hydrocephalus shunt catheter colonisation in vitro by impregnation with antimicrobials. J Neurol Neurosurg Psychiatr. 1989;52:605–609.
- Ehrlich P. Pathology in chemotherapeutics: scientific principles, methods and results. Lancet. 1913;182:445–451.
- Levin S, Harris AA. Principles of combination therapy. Bull NY Acad Med. 1975;51(9):1020–1038.
- Zhao X, Drlica K. Restricting the selection of antibiotic-resistant mutants: a general strategy derived from fluoroquinolone studies. Clin Infect Dis. 2001;33(Suppl3):S147–156.
- Urban C, Mariano N, Rahal JJ. In vitro double and triple bactericidal activities of doripenem, polymyxin B, and rifampicin against multidrug-resistant Acinetobacter baumannii Pseudomonas aeruginosa, Klebsiella pneumoniae, and Escherichia coli. Antimicrob Ag Chemother. 2010;54:2732–2734.
- Bayston R, Ashraf W, Bhundia C. Mode of action of an antimicrobial biomaterial for use in hydrocephalus shunts. J Antimicrob Chemother. 2004;53:778–782.
- Bayston R, Lambert E. Duration of protective activity of cerebrospinal fluid shunt catheters impregnated with antimicrobial agents to prevent bacterial catheter-related infection. J Neurosurg. 1997;87:27–251.
- Bayston R, Vera L, Ashraf W. Activity of an antimicrobial hydrocephalus shunt catheter against Propionibacteriumacnes. Antimicrob Agents Chemother. 2010;54:5082–5085.
- Eymann R, Chehab S, Strowitzki M, et al. Clinical and economic consequences of antibiotic-impregnated cerebrospinal fluid shunt catheters. J Neurosurg Pediatr. 2008;1:444–450.
- Edwards NC, Engelhart L, Casamento EMH, et al. Cost-consequence analysis of antibiotic-impregnated shunts and external ventricular drains in hydrocephalus. J Neurosurg. 2015;122:139–147.
- Root B, Barrena BG, Mackenzie TA, et al. Antibiotic impregnated external ventricular drains: meta and cost analysis. World Neurosurg. 2016;86:306–315.
- Mallucci CL, Jenkinson MD, Conroy EJ, et al. Antibiotic or silver versus standard ventriculoperitoneal shunts (BASICS): a multicentre, single-blinded, randomised trial and economic evaluation. Lancet. 2019;394:1530–1539.
- Wong GKC, Ip M, Poon WS, et al. Antibiotics-impregnated ventricular catheter versus systemic antibiotics for prevention of nosocomial CSF and non-CSF infections: a prospective randomised clinical trial. J Neurol Neurosurg Psychiatr. 2010;81:1064–1067.
- Belfield K, Chen X, Smith EF, et al. An antimicrobial impregnated urinary catheter that reduces mineral encrustation and prevents colonisation by multi-drug resistant organisms for up to 12 weeks. Acta Biomater. 2019;90:157–168.
- Belfield K, Betts H, Parkinson R, et al. A tolerability and patient acceptability pilot study of a novel antimicrobial urinary catheter for long-term use. Neurol Urodynamics. 2019;38:338–345.
- Tian Y, Xie X, Xiang S, et al. Risk factors and outcomes of early onset peritonitis in Chinese peritoneal dialysis patients. Kidney Blood Press Res. 2017;42:1266–1276.
- Busscher HJ, Alt V, van der Mei HC, et al. A transatlantic perspective on stagnation in clinical translation of antimicrobial strategies for the control of biomaterial-implant-associated infection. ACS Biomater Sci Eng. 2019;5(2):402–406. DOI:10.1021/acsbiomaterials.8b01071